MAZE THERAPEUTICS INC (MAZE) — insider trading
Health Care · NASDAQ
MAZE THERAPEUTICS INC (MAZE) has 25 reported SEC Form 4 insider transactions in our data, including 13 open-market sales among the most recent 25 (latest 2026-07-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 1,597 | $30.44 | $48.6K | Form 4 |
| 2026-07-01 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 30,311 | $29.95 | $907.9K | Form 4 |
| 2026-07-01 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 2,593 | $29.98 | $77.7K | Form 4 |
| 2026-07-01 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion (derivative) | 14,609 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Bernstein Harold | Officer (President, R&D & CMO) | Open-market sale | 1,200 | $30.34 | $36.4K | Form 4 |
| 2026-07-01 | Bernstein Harold | Officer (President, R&D & CMO) | Open-market sale | 13,409 | $29.87 | $400.5K | Form 4 |
| 2026-07-01 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion | 14,609 | $10.42 | $152.2K | Form 4 |
| 2026-06-29 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion (derivative) | 7,500 | $0.00 | $0 | Form 4 |
| 2026-06-29 | Dandekar Atul | Officer (CSBO) | Open-market sale | 7,500 | $28.02 | $210.2K | Form 4 |
| 2026-06-29 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion | 7,500 | $10.42 | $78.2K | Form 4 |
| 2026-06-23 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 23,865 | $26.05 | $621.7K | Form 4 |
| 2026-06-22 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 2,040 | $26.00 | $53.0K | Form 4 |
| 2026-06-22 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 1,953 | $26.00 | $50.8K | Form 4 |
| 2026-06-08 | Andrews Nancy C | Director | Grant / award / vesting (derivative) | 18,000 | $0.00 | $0 | Form 4 |
| 2026-06-08 | HOMCY CHARLES J | Director | Grant / award / vesting (derivative) | 18,000 | $0.00 | $0 | Form 4 |
| 2026-06-08 | Hoppenot Herve | Director | Grant / award / vesting (derivative) | 18,000 | $0.00 | $0 | Form 4 |
| 2026-06-08 | Lim Jonathan E | Director | Grant / award / vesting (derivative) | 18,000 | $0.00 | $0 | Form 4 |
| 2026-06-08 | SCHELLER RICHARD H | Director | Grant / award / vesting (derivative) | 18,000 | $0.00 | $0 | Form 4 |
| 2026-06-08 | SPIEGELMAN DANIEL K | Director | Grant / award / vesting (derivative) | 18,000 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion (derivative) | 14,853 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Bernstein Harold | Officer (President, R&D & CMO) | Open-market sale | 1,600 | $26.36 | $42.2K | Form 4 |
| 2026-06-01 | Bernstein Harold | Officer (President, R&D & CMO) | Open-market sale | 13,253 | $25.57 | $338.9K | Form 4 |
| 2026-06-01 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion | 14,853 | $10.42 | $154.8K | Form 4 |
| 2026-06-01 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 553 | $26.24 | $14.5K | Form 4 |
| 2026-06-01 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 6,090 | $26.20 | $159.5K | Form 4 |
Ask the chat about MAZE's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: MAZE THERAPEUTICS INC (MAZE).
Last updated 2026-07-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.